Arcturus Therapeutics resumed with an Overweight at Wells Fargo

Wells Fargo analyst Jim Birchenough resumed coverage of Arcturus Therapeutics with an Overweight rating and $35 price target. His positive view on Arcturus is based on the company’s differentiated mRNA and LNP delivery technologies, validated by its recent partnership with CSL Seqirus. Birchenough sees significant upside potential for the company’s therapeutics programs for OTC deficiency and cystic fibrosis, and views the company’s collaboration with CSL on vaccine development as a key source for capital, providing a 3-year cash runway that can support the therapeutic programs through proof-of-concept.